comprehensive -WSS

comprehensive

author：entertainment 2025-10-01 15:28:00 - browse：459

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： In his State of the Union, Biden takes clear aim at 'Big Pharma'

explore

WSS

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

Amylyx ALS drug fails large clinical trial

FDA warns medical device makers about rise in fabricated data

NEJM study link tiny plastics in blood vessels to heart problems

Change Healthcare payments predicted restored March 15

knowledge

comprehensive

explore

New air purifier tech could be key to improving indoor air quality

Reporting on presidential health from Reagan to Trump and Biden

Activists slam private health insurers over coverage restrictions

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Duchenne breakthrough therapy leaves behind pioneering families

Researchers tackle phage therapy hurdles for wider adoption

Medical leaders decry Supreme Court decision on affirmative action

Flagship Pioneering startup Sonata Therapeutics lays off 21

In age of alternative facts, a scholarly course on calling out crap

Surprise medical billing ban raises prices elsewhere

hotspot

Just how do doctors, lawmakers, and the public define abortion?

RSV shot was 90% effective at preventing hospitalizations in kids

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

NEJM study link tiny plastics in blood vessels to heart problems

The problem with charging patients to message their doctors

Elevance, SCAN deals highlight health insurer acquisition scrutiny

hotspot

explore

leisure time

entertainment